Gout: Causes, Symptoms, and How to Prevent Attacks (2026 Guide)

Gout has been called "the disease of kings" because historically it was associated with rich food and wine — but it's anything but glamorous. It causes some of the most intense pain a human being can experience. Those who've had a gout attack describe the sensation of even a bedsheet touching the affected joint as unbearable. And it affects roughly 9 million Americans — far more than historically thought, and rates are rising.

The good news: gout is one of the most preventable and treatable forms of arthritis. The key is understanding why it happens and taking consistent action to keep uric acid in check.

What Is Gout and Why Does It Cause Such Extreme Pain?

Gout is a form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and surrounding tissues. These needle-shaped crystals form when blood uric acid levels chronically exceed the saturation point — generally above 6.8 mg/dL.

When crystals form in a joint, the immune system mounts a ferocious inflammatory response. Neutrophils (white blood cells) engulf the crystals and release massive amounts of inflammatory mediators — interleukin-1β in particular — causing intense, rapid-onset inflammation. Joint fluid floods the space; pressure builds; the surrounding tissues become intensely inflamed and exquisitely sensitive. This is why even light touch causes excruciating pain during an acute attack.

Understanding Uric Acid

Uric acid is the final breakdown product of purines — compounds found naturally in many foods and produced by normal cell turnover. Most mammals have the enzyme uricase, which breaks down uric acid further. Humans lost this gene during evolution — meaning we can't clear uric acid as effectively, making us uniquely susceptible to gout.

Uric acid levels are determined by the balance between production and excretion:

• Overproduction (10–15% of gout cases): Genetic enzyme defects, high purine diet, rapid cell turnover (cancer treatment, psoriasis)
• Underexcretion (85–90% of gout cases): Kidney inefficiency at clearing uric acid — often genetic; worsened by dehydration, certain medications, kidney disease

Who Is at Risk?

• Sex: Men are affected 3–4× more often than women before menopause — estrogen promotes renal uric acid excretion. After menopause, women's rates approach men's
• Age: Risk increases with age; peak incidence in men is 40–60 years
• Genetics: Specific variants in SLC2A9 and ABCG2 transporters significantly affect uric acid levels — family history is a strong risk factor
• Kidney function: Reduced GFR reduces uric acid clearance
• Medications: Diuretics (thiazides, furosemide) are the most common medication cause; low-dose aspirin, cyclosporine, tacrolimus
• Medical conditions: Hypertension, diabetes, metabolic syndrome, chronic kidney disease, heart failure, psoriasis
• Diet and lifestyle: High-purine foods, excess alcohol (particularly beer), fructose-sweetened beverages, obesity, dehydration

Gout Stages: From High Uric Acid to Chronic Disease

Stage 1: Asymptomatic Hyperuricemia

Elevated uric acid (above 6.8 mg/dL) without symptoms. Crystals may be forming silently in joints. Not all people with hyperuricemia develop gout — but risk rises significantly with higher and longer-lasting elevated levels.

Stage 2: Acute Gout Attack

The classic presentation: sudden, severe joint pain — typically the big toe joint (podagra) in 50–70% of first attacks. Also commonly affects the ankle, knee, wrist, elbow, and fingers. Attacks often begin at night (when body temperature is lower, promoting crystal formation) and peak in intensity within 12–24 hours. The joint is hot, red, swollen, and exquisitely tender. Without treatment, attacks typically resolve in 3–14 days.

Stage 3: Intercritical Gout

The symptom-free period between attacks. Without treatment, the next attack typically comes within 1–2 years; attacks become more frequent and involve more joints over time. Crystals continue depositing silently.

Stage 4: Chronic Tophaceous Gout

With sustained hyperuricemia over years, tophi form — large deposits of urate crystals visible as firm, chalky nodules under the skin, particularly around joints, the ear, and tendons. Chronic joint damage occurs. Kidney stones (uric acid stones) develop in some patients. This stage is largely preventable with appropriate urate-lowering therapy.

Treating an Acute Gout Attack

The goal during an acute attack is rapid pain relief and reduction of inflammation. Start treatment as soon as possible — the earlier, the better.

First-Line Options

NSAIDs — naproxen (500mg twice daily) or indomethacin (50mg three times daily) are most effective when started within the first few hours of an attack. Full anti-inflammatory doses for 5–7 days. Avoid in patients with kidney disease, heart failure, or peptic ulcer history.

Colchicine — extremely effective for acute gout, particularly when started early (within 12 hours). Current evidence supports low-dose colchicine (1.2mg immediately, followed by 0.6mg one hour later) as equally effective as high-dose regimens with far fewer GI side effects. Continue 0.6mg twice daily for 7–14 days to prevent rebound.

Oral corticosteroids — prednisone 30–40mg daily for 3–5 days when NSAIDs and colchicine are contraindicated (such as in severe kidney disease). Intra-articular corticosteroid injection provides rapid relief for accessible joints.

Supportive Measures

• Rest and elevate the affected joint
• Apply ice packs (cold reduces inflammation and numbs pain) — avoid direct contact with skin
• Drink plenty of water — hydration promotes uric acid excretion
• Protect the joint from pressure — even light bedding can be unbearable; a bed cradle or blanket support helps

Urate-Lowering Therapy: Preventing Future Attacks

The cornerstone of long-term gout management is maintaining serum urate below the saturation point — ideally below 6.0 mg/dL (below 5.0 mg/dL in patients with tophi). This requires consistent medication, not just lifestyle changes alone in most cases.

When to Start Urate-Lowering Therapy

The 2020 ACR gout guidelines recommend urate-lowering therapy for patients with:

• 2 or more gout attacks per year
• Tophi (by imaging or physical exam)
• Any gout with stage ≥3 CKD
• Gout with urolithiasis (kidney stones)
• Serum urate consistently above 9 mg/dL (even after first attack)

Allopurinol — First-Line Urate-Lowering Medication

Allopurinol blocks xanthine oxidase — the enzyme that produces uric acid. It's highly effective, inexpensive, and safe for most patients. Start at 100mg/day (50mg in CKD) and titrate upward every 2–4 weeks to achieve the target serum urate below 6.0 mg/dL. Many patients ultimately need 300–600mg/day; there's no maximum dose per se, though doses above 300mg/day should be used cautiously in severe CKD.

Critical points: always start allopurinol with prophylactic colchicine (0.6mg daily) or low-dose NSAID for 3–6 months — initiating urate-lowering therapy mobilizes crystals and can trigger attacks. This is why many patients (incorrectly) blame allopurinol for worsening their gout — the prophylaxis prevents this.

Allopurinol hypersensitivity syndrome (AHS) — a rare but potentially severe reaction — is associated with the HLA-B*5801 gene variant found predominantly in Han Chinese, Thai, and Korean populations. Testing for this variant before starting allopurinol is recommended in these populations.

Febuxostat (Uloric)

An alternative xanthine oxidase inhibitor — more potent than allopurinol at equivalent doses. An FDA black box warning exists regarding cardiovascular mortality risk compared to allopurinol (from the CARES trial). Currently recommended when allopurinol is not tolerated or contraindicated, not as first-line therapy.

Probenecid

A uricosuric agent that increases renal uric acid excretion. An alternative for patients who can't tolerate xanthine oxidase inhibitors, provided kidney function is adequate and there's no history of uric acid kidney stones.

Pegloticase (Krystexxa)

For severe, refractory tophaceous gout — an IV-administered PEGylated recombinant uricase that dramatically lowers uric acid. Very effective but expensive, requires infusions every 2 weeks, and carries infusion reaction risks. Reserved for patients with serious gout unresponsive to other treatments.

Diet and Lifestyle: Reducing Uric Acid Naturally

Dietary changes alone typically reduce uric acid by 1–2 mg/dL — meaningful but usually insufficient to reach target levels in established gout. Medication remains essential for most patients with recurrent gout.

Cherries and cherry extract deserve special mention — multiple studies show associations between cherry intake and reduced gout attack risk. A Boston University study found eating cherries over 2 days was associated with a 35% lower risk of gout attacks. The mechanism appears to involve anthocyanins reducing inflammation and modestly reducing uric acid. Worth including, but not a substitute for medication.

Frequently Asked Questions